Trend Technology 7: a vaccine synthesized around one patient's tumour mutations
Summary
The report's seventh selected technology trains the immune system instead of attacking the tumour: cells are taken from a patient's tumour and sequenced to identify the antigens marking those cells as foreign, an mRNA vaccine is synthesized around that profile, and the primed immune system is ready if the cancer returns.
Classification
Main topicBio & Health Tech
Region menusGlobal
Impactscope:global
Time horizon4-10 years (2026-07-26)
Last updated2026-07-29 04:49:52
Evidence 1
- Top 10 Emerging Technologies of 2026 World Economic Forum (in collaboration with Frontiers) page=24;section=7 Personalized mRNA cancer vaccines 2026-06 accessed 2026-07-26
Observed signals 4
- SignalA $200 million public-private partnership was announced in March 2026 to fund further trials
- SignalAn estimated $79.4 billion of public investment built the mRNA infrastructure now reused
- SignalMSK trial reports 90% survival among immune responders in pancreatic cancer
- SignalPersonalized vaccine plus pembrolizumab cut recurrence or death risk by 49% in melanoma
Part of issues 4
- IssueLeft to default, benefits concentrate where capacity already exists3 trends · 0 signals
- IssuePer-patient cost above $100,000 could confine the therapy to well-resourced health systems1 trends · 0 signals
- IssueTechnology decisions move to municipal, hospital and regional actors3 trends · 1 signals
- IssueTrust is a precondition, not a soft variable, because the arrangements have no precedent3 trends · 1 signals
Relation types: constitutes · supports
Public id: fm-fce9a5d669fc